The Journal of Clinical Psychiatry

Article January 9, 2001

Clozapine: Diabetes Mellitus, Weight Gain, and Lipid Abnormalities

J Clin Psychiatry 2001;62(suppl 23):39-44

Article Abstract

Clozapine remains the most effective agent for treatment-resistant patients with schizophrenia.Recently, treatment with clozapine has been linked to a number of metabolic disturbances, includingweight gain, diabetes mellitus, and serum lipid abnormalities. Despite the potential risks of medicalmorbidities, clozapine continues to have a major role in the care of treatment-resistant patients withschizophrenia. This article discusses the diagnosis and significance of the above metabolic abnormalitiesand potential mechanisms for these abnormalities as well as recommendations for monitoring andtreatment.

 

This PDF is free for all visitors!